Reuters logo
2 个月内
BRIEF-Oncoquest announces enrollment of first patient in phase 1/2 clinical study
2017年5月9日 / 中午11点34分 / 2 个月内

BRIEF-Oncoquest announces enrollment of first patient in phase 1/2 clinical study

1 分钟阅读

May 9 (Reuters) - Quest Pharmatech Inc:

* Oncoquest announces enrollment of first patient in phase 1/2 clinical study using combination of oregovomab with checkpoint inhibitor nivolumab in recurrent ovarian cancer Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below